Mechanistically, TAC alleviated hepatic lipid accumulation by modulating the activity of key lipometabolic enzymes (HL, LPL, HMGCR), thereby exerting therapeutic effects against hyperlipidemia-combined hepatic steatosis. Here, HMGCR is linked to Hepatic steatosis.